Eli Lilly & Co.

Oncology and Haematologic Malignancies

Clinical research includes breast cancer, non-small cell lung cancer, prostate cancer, colorectal cancer, pancreatic cancer, ovarian cancer, urothelial carcinoma, thyroid cancer, and other solid tumours, with additional studies in glioma, neuroblastoma, and advanced hematologic malignancies.

  • Metastatic and advanced solid tumours
  • Genomically defined cancers
  • Breast, lung, prostate, and gastrointestinal cancers
  • Brain tumours and paediatric oncology

Research activity also covers tumour subtypes linked to KRAS, RET, FGFR3, IDH1, and IDH2 alterations.

Metabolic, Cardiovascular, and Renal Disorders

Studies focus on type 2 diabetes, type 1 diabetes, obesity, overweight, hypertension, atherosclerotic cardiovascular disease, heart failure with preserved ejection fraction, peripheral arterial disease, and chronic kidney disease.

  • Diabetes and beta-cell preservation
  • Weight management and obesity-related disease
  • Cardiovascular risk reduction
  • Kidney function and renal impairment

Additional interest includes lipoprotein(a) and broader lipid disorders in people at elevated cardiovascular risk.

Immunology, Inflammation, and Autoimmune Disease

The sponsor funds trials in rheumatoid arthritis, juvenile idiopathic arthritis, uveitis, atopic dermatitis, alopecia areata, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases.

  • Inflammatory arthritis
  • Skin and hair autoimmune conditions
  • Ocular inflammation
  • Gastrointestinal immune-mediated disease

Research also extends to connective tissue diseases and immune system diseases across adult and paediatric populations.

Neurology, Neurodegeneration, and Migraine

Clinical programmes address Alzheimer disease, dementia, relapsing multiple sclerosis, sporadic amyotrophic lateral sclerosis, chronic migraine, and episodic migraine, alongside broader central nervous system diseases and neurocognitive disorders.

  • Alzheimer’s disease and cognitive decline
  • Multiple sclerosis
  • Motor neuron disease
  • Paediatric and adolescent migraine

Research interest includes disorders affecting the nervous system and neurodegenerative diseases across different stages of life.

Respiratory, Sleep, Pain, and Other Chronic Conditions

Additional studies cover asthma, chronic rhinosinusitis with nasal polyps, obstructive sleep apnea, osteoarthritis, chronic low back pain, neuropathic pain, stress urinary incontinence, nausea, and vomiting.

  • Airway and allergic disease
  • Sleep-disordered breathing
  • Musculoskeletal pain and joint disease
  • Urological symptoms and supportive care

Trial activity also includes chronic pain syndromes and other symptomatic conditions affecting daily function.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of Abemaciclib with Irinotecan and Temozolomide for Children and Young Adults with Relapsed or Refractory Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Spain
  • Study of LY3541860 and Meglumine Gadoterate for Adults with Relapsing Multiple Sclerosis

    Not recruiting

    2 1 1
    Investigated diseases:
    France Germany Italy Latvia Lithuania Poland +1
  • Study of Fulvestrant and Abemaciclib for Women with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Greece Italy Poland Spain
  • Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +8
  • Study of Eltrekibart for Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    2 1
    Investigated diseases:
    Germany Greece Poland
  • Study on Selpercatinib for Adults with Advanced or Metastatic Solid Tumors with RET Activation

    Not recruiting

    3 1 1 1
    Investigated drugs:
    France Italy Poland Spain